


Come to Hungary



*The fourteen-year History of C1
inhibitor Deficiency workshops*

Iceland

1st C1 inh
1999
14 countries



Sweden Great Britain Netherlands

Norway Poland

Hungary

Austria Belgium Czech Republic France Italy Germany

Spain

1st C1 inh
Def. Workshop

14 countries 1999



Norway



Sweden



Hungary



Swiss



Austria



Belgium



France



Italy



Poland




Spain



UK



The Netherlands



German



Czech Rep



UK



The Netherlands

*2nd C1
inh.Def.Worksh
2001
15 countries*



*3rd CI
inh.Def.Worksh 2003
17 countries*



Canada



Ukraine



Romania



Argentina

4th C1 Inh.Def. Workshop 2005


23
countries



Macedonia




Bulgaria



Russia



Iran



China

5th C1 Inh.Def. Workshop 2007

19 countries



Israel

6th C1 Inh.Def. Workshop 2009

24
countries



Finland

South Africa

Brazil

Greece

Egypt

7th C1 Inh.Def. Workshop 2011

27 countries



Slovenia



Turkey




Portugal

8th C1 Inh.Def. Workshop 2013

34 countries



Mexico



Algeria



Australia




Belarus



Estonia



Ireland



Japan

© SCHROETER-DESIGN.DE





8th C1 Inhibitor Deficiency Workshop

14 years

40 countries




Short History of C1-INH Workshops in HUNGARY





*1st C1 Esterase
Inhibitor*

*Deficiency Workshop
14-16 May, 1999*



*Hungary
Visegrád*


Some impressions on the first Workshop 1999





*2nd
C1 Esterase Inhibitor
Deficiency Workshop
20-22 April, 2001*

Budapest 



The second Workshop 2001



After the scientific program we had some fun



Patients representative



Anti-C1INH antibodies of IgM is

		IgM normal range 0-21%				
		Group B			Group C	
		Subj 5	Subj 6	Subj 9	Subj 12	Subj 13
	12.5 U/kg	205	10	13	7	6
	25 U/kg	205	4	13	3	7
	50 U/kg	0	7	41	3	0
	100 U/kg	0	7	27	1	4
	50 U/kg	5	0	0	7	5
	100 U/kg	2	0	0	7	5
	50 U/kg	2	0	0	8	5
	100 U/kg	2	0	0	4	5
	50 U/kg	10	13	10	4	4
	100 U/kg					



First HAE Award

























Welcome to Budapest again in 2005

CI INHIBITOR DEFICIENCY WORKSHOP
29 April - 1 May
2005


BUDAPEST



HAE Award 2005



Ferenc Cakó




Illusionist

dance band
SONNY

COTTON
CLUB





Visit in the Parlament



*2007
HAE Award
Marco Cicardi*



31 MAY-3 JUNE 2007 BUDAPEST

Cooperation comings and goings



*Helping,
bringing,
couching...*



Dinner at Sir Lancelot



Looking for needle in the hayloft



2009



6th CIHW Deficiency Workshop
22-24 May Budapest / Hungary




*2009 HAE Award
Konrad Bork*









Synchron swimming









Les presidents






The highest floor activity











Angio-RMN

Hypoperfusion of the sylvian territories on the L side.











Special HAE TEAM performance





OLD TIME DANCING





2011





*HAE Award
2011
Michael Frank
Allan Kaplan*







P-05

Clinical immunological and biochemical aspects of pathogenesis, diagnostics and treatment of the hereditary form of angioneurotic edema.

Zabrodskaya L.V. Koltz Institute of Hereditary and Autoimmune Diseases

The thesis is devoted to the study of pathogenesis of hereditary form of angioneurotic edema (HAE) in patients with deficiency of C1-inhibitor (C1-INH) and its biochemical, immunological and clinical aspects. All patients with HAE were examined by immunological and biochemical methods. The results of the study are presented in the form of graphs and tables.

For the first time the diagnostic value of the study of C1-INH activity and its biochemical, immunological and clinical aspects in patients with HAE was demonstrated. The results of the study are presented in the form of graphs and tables.



P-04

Use of a Simulation Suite to Compare the Administration of Drugs Used to Treat Hereditary Angioedema in an Emergency Setting

Dr. [Name] - [Institution]

Background: Hereditary angioedema (HAE) is a life-threatening condition characterized by recurrent episodes of swelling. The administration of drugs used to treat HAE in an emergency setting is a complex task. This study compares the administration of these drugs using a simulation suite.

Methods: A simulation suite was used to compare the administration of drugs used to treat HAE in an emergency setting. The simulation suite was used to compare the administration of these drugs using a simulation suite.



P-08

Clinical outcomes with recombinant human C1 inhibitor in the rapid treatment of acute attacks of hereditary angioedema in North American patients

Dr. [Name] - [Institution]

Background: Hereditary angioedema (HAE) is a life-threatening condition characterized by recurrent episodes of swelling. The administration of recombinant human C1 inhibitor (C1-INH) is a key component of the rapid treatment of acute attacks of HAE in North American patients.

Methods: Clinical outcomes were evaluated in North American patients with HAE who received recombinant human C1-INH for the rapid treatment of acute attacks.



Poster and culinary sections





2013

HAE Award









SZEKÉR CSARDA











www.mmmmm.com



































This was a great and very fruitful meeting
Expressed by all of the attendees; includes Diamond
company

General

The satisfaction of Konrad Bork

Milan group: the

to the right context
pattern recognizing

tion – interconnection

ng the move

C1-INH-D WS



DANUBIUS
HEALTH SPA RESORT

MARGITSZIGET

DANUBIUS





Our fugacy – but life is going on

The spiritus rector is dead – let's hurrah the Angels

Have a safe trip home
See you latest in two years

2015

- Awards
- Experts' lectures
- Basic science
- Genetics
- Trials
- Treatment options
- Diagnosis
- HAE-nC1-INH
- Scoring & QoL
- Registries, Cohorts, Centers, Organisations
- Farewell



Have a nice HAE Workshop in 2015

